{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:06:44Z","timestamp":1795122404121,"version":"4.10.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key R&D Program","award":["2022YFC2401500"],"award-info":[{"award-number":["2022YFC2401500"]}]},{"name":"Science and Technology Plan Project of Chengguan District of Lanzhou","award":["No.2020-2-2-5"],"award-info":[{"award-number":["No.2020-2-2-5"]}]},{"name":"Talent innovation and venture project of Lanzhou city","award":["No. 2021-RC-125; No.2020-RC-113"],"award-info":[{"award-number":["No. 2021-RC-125; No.2020-RC-113"]}]},{"name":"Key R&D Program of Science and Technology Department of Gansu Province","award":["No. 20YF8FA116"],"award-info":[{"award-number":["No. 20YF8FA116"]}]},{"name":"Project supported by China Foundation for International Medical Exchange","award":["No. Z-2017-24-2108"],"award-info":[{"award-number":["No. Z-2017-24-2108"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and purpose<\/jats:title>\n                <jats:p>Particle therapy, mainly including carbon-ion radiotherapy (CIRT) and proton beam therapy (PBT), has dose distribution advantages compared to photon radiotherapy. It has been widely reported as a promising treatment method for early non-small cell lung cancer (NSCLC). However, its application in locally advanced non-small cell lung cancer (LA-NSCLC) is relatively rare, and its efficacy and safety are inconclusive. This study aimed to provide systematic evidence for evaluating the efficacy and safety of particle therapy for inoperable LA-NSCLC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To retrieve published literature, a systematic search was conducted in PubMed, Web of Science, Embase, and Cochrane Library until September 4, 2022. The primary endpoints were local control (LC) rate, overall survival (OS) rate, and progression-free survival (PFS) rate at 2 and 5 years. The secondary endpoint was treatment-related toxicity. The pooled clinical outcomes and 95% confidence intervals (CIs) were calculated by using STATA 15.1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nineteen eligible studies with a total sample size of 851 patients were included. The pooled data demonstrated that the OS, PFS, and LC rates at 2 years of LA-NSCLC treated by particle therapy were 61.3% (95% CI\u2009=\u200954.7-68.7%), 37.9% (95% CI\u2009=\u200933.8-42.6%) and 82.2% (95% CI\u2009=\u200978.7-85.9%), respectively. The pooled 5-year OS, PFS, and LC rates were 41.3% (95% CI\u2009=\u200927.1-63.1%), 25.3% (95% CI\u2009=\u200916.3-39.4%), and 61.5% (95% CI\u2009=\u200950.7-74.6%), respectively. Subgroup analysis stratified by treatment type showed that the concurrent chemoradiotherapy (CCRT, PBT combined with concurrent chemotherapy) group had better survival benefits than the PBT and CIRT groups. The incidence rates of grade 3\/4 esophagitis, dermatitis, and pneumonia in LA-NSCLC patients after particle therapy were 2.6% (95% CI\u2009=\u20090.4-6.0%), 2.6% (95% CI\u2009=\u20090.5-5.7%) and 3.4% (95% CI\u2009=\u20091.4-6.0%), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Particle therapy demonstrated promising efficacy and acceptable toxicity in LA-NSCLC patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02264-x","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:01:44Z","timestamp":1684753304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Yanliang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"1","key":"2264_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2264_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","volume":"41","author":"BC Bade","year":"2020","unstructured":"Bade BC, Dela Cruz CS. Lung Cancer 2020: epidemiology, etiology, and Prevention. Clin Chest Med. 2020;41(1):1\u201324. https:\/\/doi.org\/10.1016\/j.ccm.2019.10.001.","journal-title":"Clin Chest Med"},{"issue":"10125","key":"2264_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3.","journal-title":"Lancet"},{"issue":"12","key":"2264_CR4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, et al. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1994.","journal-title":"Ann Oncol"},{"issue":"7","key":"2264_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.19.01162","volume":"38","author":"JD Bradley","year":"2020","unstructured":"Bradley JD, et al. Long-term results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy with or without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(7):706\u201314. https:\/\/doi.org\/10.1200\/JCO.19.01162.","journal-title":"J Clin Oncol"},{"issue":"19","key":"2264_CR6","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jnci\/djr325","volume":"103","author":"WJ Curran Jr","year":"2011","unstructured":"Curran WJ Jr, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452\u201360. https:\/\/doi.org\/10.1093\/jnci\/djr325.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2264_CR7","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","volume":"17","author":"K Furuse","year":"1999","unstructured":"Furuse K, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692\u20139. https:\/\/doi.org\/10.1200\/JCO.1999.17.9.2692.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2264_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, et al. Five-year survival outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2264_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/00005344-198105000-00005","volume":"3","author":"C Semeraro","year":"1981","unstructured":"Semeraro C, et al. Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug. J Cardiovasc Pharmacol. 1981;3(3):455\u201367. https:\/\/doi.org\/10.1097\/00005344-198105000-00005.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"2264_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ijrobp.2004.04.013","volume":"60","author":"R Rengan","year":"2004","unstructured":"Rengan R, et al. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;60(3):741\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.04.013.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2264_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","volume":"82","author":"M Machtay","year":"2012","unstructured":"Machtay M, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012;82(1):425\u201334. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.09.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2264_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"JD Bradley","year":"2015","unstructured":"Bradley JD, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(14)71207-0.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2264_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4143\/crt.2021.299","volume":"53","author":"KS Kim","year":"2021","unstructured":"Kim KS, Wu HG. Who will benefit from charged-particle therapy? Cancer Res Treat. 2021;53(3):621\u201334. https:\/\/doi.org\/10.4143\/crt.2021.299.","journal-title":"Cancer Res Treat"},{"key":"2264_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.01.024","author":"S Gaito","year":"2023","unstructured":"Gaito S, et al. Outcomes of patients treated in the UK Proton Overseas Programme: Central Nervous System Group. Clin Oncol (R Coll Radiol). 2023. https:\/\/doi.org\/10.1016\/j.clon.2023.01.024.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2264_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.02.009","author":"E Hwang","year":"2023","unstructured":"Hwang E, et al. Outcomes of patients treated in the UK Proton Overseas Programme: non-central nervous System Group. Clin Oncol (R Coll Radiol). 2023. https:\/\/doi.org\/10.1016\/j.clon.2023.02.009.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"8","key":"2264_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.clon.2021.03.009","volume":"33","author":"S Gaito","year":"2021","unstructured":"Gaito S, et al. Skin toxicity Profile of Photon Radiotherapy versus Proton Beam Therapy in Paediatric and Young Adult Patients with Sarcomas. Clin Oncol (R Coll Radiol). 2021;33(8):507\u201316. https:\/\/doi.org\/10.1016\/j.clon.2021.03.009.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1133","key":"2264_CR17","doi-asserted-by":"publisher","first-page":"20211175","DOI":"10.1259\/bjr.20211175","volume":"95","author":"NG Burnet","year":"2022","unstructured":"Burnet NG, et al. Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy. Br J Radiol. 2022;95(1133):20211175. https:\/\/doi.org\/10.1259\/bjr.20211175.","journal-title":"Br J Radiol"},{"key":"2264_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ctrv.2015.12.007","volume":"43","author":"J Doyen","year":"2016","unstructured":"Doyen J, et al. Proton beams in cancer treatments: clinical outcomes and dosimetric comparisons with photon therapy. Cancer Treat Rev. 2016;43:104\u201312. https:\/\/doi.org\/10.1016\/j.ctrv.2015.12.007.","journal-title":"Cancer Treat Rev"},{"key":"2264_CR19","doi-asserted-by":"publisher","first-page":"708724","DOI":"10.3389\/fonc.2021.708724","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, et al. Application of Carbon Ion and its sensitizing Agent in Cancer Therapy: a systematic review. Front Oncol. 2021;11:708724. https:\/\/doi.org\/10.3389\/fonc.2021.708724.","journal-title":"Front Oncol"},{"issue":"3","key":"2264_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4143\/crt.2021.066","volume":"53","author":"HK Byun","year":"2021","unstructured":"Byun HK, et al. Physical and biological characteristics of particle therapy for oncologists. Cancer Res Treat. 2021;53(3):611\u201320. https:\/\/doi.org\/10.4143\/crt.2021.066.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"2264_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.radonc.2009.08.003","volume":"95","author":"JP Grutters","year":"2010","unstructured":"Grutters JP, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol. 2010;95(1):32\u201340. https:\/\/doi.org\/10.1016\/j.radonc.2009.08.003.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2264_CR22","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.ijrobp.2006.01.052","volume":"65","author":"JY Chang","year":"2006","unstructured":"Chang JY, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65(4):1087\u201396. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.01.052.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"2264_CR23","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1002\/cncr.26080","volume":"117","author":"JY Chang","year":"2011","unstructured":"Chang JY, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011;117(20):4707\u201313. https:\/\/doi.org\/10.1002\/cncr.26080.","journal-title":"Cancer"},{"issue":"3","key":"2264_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.radonc.2015.05.014","volume":"115","author":"QN Nguyen","year":"2015","unstructured":"Nguyen QN, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015;115(3):367\u201372. https:\/\/doi.org\/10.1016\/j.radonc.2015.05.014.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2264_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.21873\/anticanres.13963","volume":"40","author":"M Anzai","year":"2020","unstructured":"Anzai M, et al. Safety and Efficacy of Carbon-ion Radiotherapy alone for stage III non-small cell Lung Cancer. Anticancer Res. 2020;40(1):379\u201386. https:\/\/doi.org\/10.21873\/anticanres.13963.","journal-title":"Anticancer Res"},{"issue":"2","key":"2264_CR26","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/cas.13890","volume":"110","author":"K Hayashi","year":"2019","unstructured":"Hayashi K, et al. Clinical outcomes of carbon-ion radiotherapy for locally advanced non-small-cell lung cancer. Cancer Sci. 2019;110(2):734\u201341. https:\/\/doi.org\/10.1111\/cas.13890.","journal-title":"Cancer Sci"},{"issue":"5","key":"2264_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341. https:\/\/doi.org\/10.1016\/j.ijsu.2010.02.007.","journal-title":"Int J Surg"},{"issue":"9","key":"2264_CR28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"key":"2264_CR29","doi-asserted-by":"publisher","unstructured":"Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10(4). https:\/\/doi.org\/10.1002\/sim.4780100410. 585 \u2013 98.","DOI":"10.1002\/sim.4780100410"},{"key":"2264_CR30","doi-asserted-by":"publisher","unstructured":"van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18(6). https:\/\/doi.org\/10.1002\/(sici)1097-0258(19990330)18:6<681::aid-sim71>3.0.co;2-r. 681 \u2013 94.","DOI":"10.1002\/(sici)1097-0258(19990330)18:6<681::aid-sim71>3.0.co;2-r"},{"issue":"4","key":"2264_CR31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ijrobp.2010.06.024","volume":"81","author":"H Nakayama","year":"2011","unstructured":"Nakayama H, et al. Proton beam therapy of stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):979\u201384. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.06.024.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2264_CR32","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/JTO.0b013e31823c485f","volume":"7","author":"Y Oshiro","year":"2012","unstructured":"Oshiro Y, et al. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2012;7(2):370\u20135. https:\/\/doi.org\/10.1097\/JTO.0b013e31823c485f.","journal-title":"J Thorac Oncol"},{"key":"2264_CR33","doi-asserted-by":"publisher","unstructured":"Hatayama Y, et al. Preliminary results of proton-beam therapy for stage III non-small-cell lung cancer. Curr Oncol. 2015;22(5). https:\/\/doi.org\/10.3747\/co.22.2523. p. e370-5.","DOI":"10.3747\/co.22.2523"},{"issue":"5","key":"2264_CR34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/jrr\/rru034","volume":"55","author":"Y Oshiro","year":"2014","unstructured":"Oshiro Y, et al. High-dose concurrent chemo-proton therapy for stage III NSCLC: preliminary results of a phase II study. J Radiat Res. 2014;55(5):959\u201365. https:\/\/doi.org\/10.1093\/jrr\/rru034.","journal-title":"J Radiat Res"},{"issue":"1","key":"2264_CR35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ijrobp.2015.11.004","volume":"95","author":"BS Hoppe","year":"2016","unstructured":"Hoppe BS, et al. Phase 2 trial of concurrent chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: results and reflections following early Closure of a Single-Institution Study. Int J Radiat Oncol Biol Phys. 2016;95(1):517\u201322. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.11.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2264_CR36","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/cas.12955","volume":"107","author":"H Harada","year":"2016","unstructured":"Harada H, et al. Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer. Cancer Sci. 2016;107(7):1018\u201321. https:\/\/doi.org\/10.1111\/cas.12955.","journal-title":"Cancer Sci"},{"issue":"8","key":"2264_CR37","doi-asserted-by":"publisher","first-page":"e172032","DOI":"10.1001\/jamaoncol.2017.2032","volume":"3","author":"JY Chang","year":"2017","unstructured":"Chang JY, et al. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: final results of a phase 2 study. JAMA Oncol. 2017;3(8):e172032. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2032.","journal-title":"JAMA Oncol"},{"key":"2264_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.radonc.2019.03.029","volume":"136","author":"A Elhammali","year":"2019","unstructured":"Elhammali A, et al. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol. 2019;136:136\u201342. https:\/\/doi.org\/10.1016\/j.radonc.2019.03.029.","journal-title":"Radiother Oncol"},{"issue":"5","key":"2264_CR39","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.ijrobp.2020.11.035","volume":"109","author":"H Iwata","year":"2021","unstructured":"Iwata H, et al. Concurrent Chemo-Proton Therapy using Adaptive Planning for Unresectable Stage 3 Non-Small Cell Lung Cancer: a phase 2 study. Int J Radiat Oncol Biol Phys. 2021;109(5):1359\u201367. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.11.035.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2264_CR40","doi-asserted-by":"publisher","unstructured":"Kim N, et al. Clinical outcomes of Pencil Beam scanning Proton Therapy in locally Advanced Non-Small Cell Lung Cancer: propensity score analysis. Cancers (Basel). 2021;13(14). https:\/\/doi.org\/10.3390\/cancers13143497.","DOI":"10.3390\/cancers13143497"},{"issue":"9","key":"2264_CR41","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/1759-7714.13896","volume":"12","author":"K Ohnishi","year":"2021","unstructured":"Ohnishi K, et al. Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer. Thorac Cancer. 2021;12(9):1320\u20137. https:\/\/doi.org\/10.1111\/1759-7714.13896.","journal-title":"Thorac Cancer"},{"key":"2264_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.01.012","author":"J Contreras","year":"2022","unstructured":"Contreras J, et al. Phase I study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2022. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.01.012.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2264_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.03.005","author":"BS Hoppe","year":"2022","unstructured":"Hoppe BS, et al. Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: a YYY phase 1\/2 trial. Int J Radiat Oncol Biol Phys. 2022. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.03.005.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2264_CR44","doi-asserted-by":"publisher","first-page":"e0175589","DOI":"10.1371\/journal.pone.0175589","volume":"12","author":"K Shirai","year":"2017","unstructured":"Shirai K, et al. Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study. PLoS ONE. 2017;12(4):e0175589. https:\/\/doi.org\/10.1371\/journal.pone.0175589.","journal-title":"PLoS ONE"},{"issue":"2","key":"2264_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.21873\/anticanres.12298","volume":"38","author":"JI Saitoh","year":"2018","unstructured":"Saitoh JI, et al. A phase I study of Hypofractionated Carbon-ion Radiotherapy for Stage III Non-small Cell Lung Cancer. Anticancer Res. 2018;38(2):885\u201391. https:\/\/doi.org\/10.21873\/anticanres.12298.","journal-title":"Anticancer Res"},{"issue":"6","key":"2264_CR46","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1097\/JTO.0b013e318288ab02","volume":"8","author":"H Iwata","year":"2013","unstructured":"Iwata H, et al. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2bN0M0) non-small-cell lung cancer. J Thorac Oncol. 2013;8(6):726\u201335. https:\/\/doi.org\/10.1097\/JTO.0b013e318288ab02.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2264_CR47","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","volume":"89","author":"C Tang","year":"2014","unstructured":"Tang C, et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014;89(5):1084\u201391. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.04.025.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2264_CR48","doi-asserted-by":"publisher","unstructured":"Brahmer J, et al. Nivolumab versus Docetaxel in Advanced squamous-cell non-small-cell Lung Cancer. N Engl J Med. 2015;373(2). https:\/\/doi.org\/10.1056\/NEJMoa1504627. 123 \u2013 35.","DOI":"10.1056\/NEJMoa1504627"},{"issue":"2","key":"2264_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jtho.2016.09.134","volume":"12","author":"CK Speirs","year":"2017","unstructured":"Speirs CK, et al. Heart dose is an independent dosimetric predictor of overall survival in locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):293\u2013301. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.134.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2264_CR50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1748-717X-8-144","volume":"8","author":"AT Berman","year":"2013","unstructured":"Berman AT, et al. An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer. Radiat Oncol. 2013;8(1):144. https:\/\/doi.org\/10.1186\/1748-717X-8-144.","journal-title":"Radiat Oncol"},{"issue":"4","key":"2264_CR51","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cllc.2011.03.027","volume":"12","author":"RC Nichols","year":"2011","unstructured":"Nichols RC, et al. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer. 2011;12(4):252\u20137. https:\/\/doi.org\/10.1016\/j.cllc.2011.03.027.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"2264_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0360-3016(00)01374-2","volume":"49","author":"M Mehta","year":"2001","unstructured":"Mehta M, et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;49(1):23\u201333. https:\/\/doi.org\/10.1016\/s0360-3016(00)01374-2.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2264_CR53","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1080\/02841860152619124","volume":"40","author":"JF Fowler","year":"2001","unstructured":"Fowler JF. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol. 2001;40(6):712\u20137. https:\/\/doi.org\/10.1080\/02841860152619124.","journal-title":"Acta Oncol"},{"issue":"10","key":"2264_CR54","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/JTO.0b013e31829f6c55","volume":"8","author":"BL Ramaekers","year":"2013","unstructured":"Ramaekers BL, et al. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients. J Thorac Oncol. 2013;8(10):1295\u2013307. https:\/\/doi.org\/10.1097\/JTO.0b013e31829f6c55.","journal-title":"J Thorac Oncol"},{"key":"2264_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.10.014","author":"YH Kim","year":"2022","unstructured":"Kim YH, et al. Randomized, multicenter, phase III study of accelerated fraction radiotherapy with concomitant boost to the gross tumor volume compared with conventional fractionation in concurrent chemoradiation in patients with unresectable stage III non-small cell lung cancer: the korean Radiation Oncology Group 09 \u2013 03 trial. Int J Radiat Oncol Biol Phys. 2022. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.10.014.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2264_CR56","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.radonc.2020.04.033","volume":"148","author":"K Glinski","year":"2020","unstructured":"Glinski K, et al. Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: a phase I\/II study. Radiother Oncol. 2020;148:174\u201380. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.033.","journal-title":"Radiother Oncol"},{"key":"2264_CR57","doi-asserted-by":"publisher","unstructured":"Kaster TS, et al. Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer. 2015;16(2). https:\/\/doi.org\/10.1016\/j.cllc.2014.08.002. 71 \u2013 9.","DOI":"10.1016\/j.cllc.2014.08.002"},{"issue":"5","key":"2264_CR58","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.prro.2021.06.004","volume":"11","author":"B Qiu","year":"2021","unstructured":"Qiu B, et al. Hypofractionated Intensity Modulated Radiation Therapy with Concurrent Chemotherapy in locally Advanced Non-Small Cell Lung Cancer: a phase II prospective clinical trial (GASTO1011). Pract Radiat Oncol. 2021;11(5):374\u201383. https:\/\/doi.org\/10.1016\/j.prro.2021.06.004.","journal-title":"Pract Radiat Oncol"},{"issue":"20","key":"2264_CR59","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"issue":"24","key":"2264_CR60","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, et al. Overall survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1809697.","journal-title":"N Engl J Med"},{"issue":"1","key":"2264_CR61","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12672-022-00586-y","volume":"13","author":"Y Wan","year":"2022","unstructured":"Wan Y, et al. Prognostic value of beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer. Discov Oncol. 2022;13(1):127. https:\/\/doi.org\/10.1007\/s12672-022-00586-y.","journal-title":"Discov Oncol"},{"issue":"3","key":"2264_CR62","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.radonc.2017.05.007","volume":"123","author":"A Chi","year":"2017","unstructured":"Chi A, et al. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review and hypothesis-generating meta-analysis. Radiother Oncol. 2017;123(3):346\u201354. https:\/\/doi.org\/10.1016\/j.radonc.2017.05.007.","journal-title":"Radiother Oncol"},{"key":"2264_CR63","doi-asserted-by":"publisher","unstructured":"Li J et al. Additional Postoperative Radiotherapy Prolonged the Survival of Patients with I-IIA Small Cell Lung Cancer: Analysis of the SEER Database. J Oncol, 2022. 2022: p.\u00a06280538. https:\/\/doi.org\/10.1155\/2022\/6280538.","DOI":"10.1155\/2022\/6280538"},{"issue":"13 Pt 2","key":"2264_CR64","doi-asserted-by":"publisher","first-page":"5045s","DOI":"10.1158\/1078-0432.CCR-05-9008","volume":"11","author":"EE Vokes","year":"2005","unstructured":"Vokes EE, et al. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res. 2005;11(13 Pt 2):5045s\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-9008.","journal-title":"Clin Cancer Res"},{"key":"2264_CR65","doi-asserted-by":"publisher","unstructured":"Onishi H, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a japanese multi-institutional study. J Thorac Oncol. 2007;3https:\/\/doi.org\/10.1097\/JTO.0b013e318074de34. 2(7 Suppl) p. S94-100.","DOI":"10.1097\/JTO.0b013e318074de34"},{"issue":"3","key":"2264_CR66","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/s0360-3016(01)01703-5","volume":"51","author":"M Uematsu","year":"2001","unstructured":"Uematsu M, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51(3):666\u201370. https:\/\/doi.org\/10.1016\/s0360-3016(01)01703-5.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2264_CR67","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.1038\/s41598-021-85131-7","volume":"11","author":"M Or","year":"2021","unstructured":"Or M, et al. A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer. Sci Rep. 2021;11(1):5939. https:\/\/doi.org\/10.1038\/s41598-021-85131-7.","journal-title":"Sci Rep"},{"issue":"1","key":"2264_CR68","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","volume":"35","author":"SG Chun","year":"2017","unstructured":"Chun SG, et al. Impact of intensity-modulated Radiation Therapy technique for locally Advanced Non-Small-Cell Lung Cancer: a secondary analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017;35(1):56\u201362. https:\/\/doi.org\/10.1200\/JCO.2016.69.1378.","journal-title":"J Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02264-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02264-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02264-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:06:37Z","timestamp":1684753597000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02264-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2264"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02264-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"21 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}